Back to resultsExpanded Access to NanoDoce
Primary Purpose
Urogenital Neoplasms
Status
Available
Phase
Locations
Study Type
Expanded Access
Intervention
NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension
Sponsored by
About this trial
This is an expanded access trial for Urogenital Neoplasms
Eligibility Criteria
Inclusion Criteria:
-
Exclusion Criteria:
-
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT04060628
First Posted
August 14, 2019
Last Updated
April 7, 2022
Sponsor
NanOlogy, LLC
Collaborators
US Biotest, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT04060628
Brief Title
Expanded Access to NanoDoce
Official Title
Expanded Access to NanoDoce
Study Type
Expanded Access
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
NanOlogy, LLC
Collaborators
US Biotest, Inc.
4. Oversight
5. Study Description
Brief Summary
NanOlogy may consider offering expanded access to NanoDoce for patients who do not meet the enrollment criteria of clinical trials in progress.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urogenital Neoplasms
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension
Other Intervention Name(s)
docetaxel
10. Eligibility
Eligibility Criteria
Inclusion Criteria:
-
Exclusion Criteria:
-
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Gere diZerega, MD
Phone
805-595-1300
Email
gere.dizerega@usbiotest.com
12. IPD Sharing Statement
Learn more about this trial
Expanded Access to NanoDoce
We'll reach out to this number within 24 hrs